Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Funding Helped By Ebola Emergency Spending, But Opioid Issue Still Rankles Appropriators

This article was originally published in RPM Report

Executive Summary

Spending agreement includes $137 more for FDA—most from user fee increases previously enacted. Still, discretionary budget does go up for FDA, albeit at the cost of a rider demanding final action on abuse-deterrent formulation guidance by June.

You may also be interested in...



Seeking Guidance On Abuse-Deterrence: Sponsors Fall Short, Congress Urges Action

Congressional appropriators are urging FDA to move quickly to finalize guidance on abuse deterrence claims for opioids—and to take the next step and prohibit marketing of products that don’t deter abuse. FDA says the science isn’t there yet, and two sponsors join the list of those who have failed to clear the hurdle.

FDA Opioid Guidance Is Silent On Generics, Cautions That Addicts Can Erase Labeling

Draft guidance on abuse-deterrent opioids notes that labeling claims may be revised if abusers outwit the abuse-resistant technology; the agency’s evaluation of generic-related citizen petitions continues.

Biogen/Eisai’s Lecanemab Suggests A New Model For Accelerated Approval In The US

Why not wait for the confirmatory trial to read out before approval, at least in the context of an especially uncertain or controversial surrogate marker?

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS079761

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel